THRX Stock Price, Theseus Pharmaceuticals, . Quote, Chart

Market Summary

USD4.06

Delayed

THRX Stock Price

View Fullscreen

THRX RSI Chart

THRX Valuation

Market Cap

179.6M

Price/Earnings (Trailing)

-3.17

Price/Free Cashflow

-3.62

THRX Price/Earnings (Trailing)

THRX Profitability

Return on Equity

-25.21%

Return on Assets

-24.13%

Free Cashflow Yield

-27.65%

THRX Fundamentals

THRX Earnings

Earnings (TTM)

-56.6M

Earnings Growth (Yr)

8.42%

Earnings Growth (Qtr)

8.79%

Breaking Down THRX Revenue

Last 30 days

1.5%

Last 90 days

12.2%

Trailing 12 Months

-64.4%

How does THRX drawdown profile look like?

THRX Financial Health

Current Ratio

29.93

THRX Investor Care

Shares Dilution (1Y)

14.25%

Diluted EPS (TTM)

-1.35

Tracking the Latest Insider Buys and Sells of Theseus Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 14, 2024	dahms bradford d.	sold	-	-	-8,150	president and cfo
Feb 14, 2024	dukes iain d.	sold	-	-	-388,324	-
Feb 14, 2024	gordon carl l	sold	-	-	-17,713,600	-
Feb 14, 2024	hayden donald j jr	sold	-	-	-10,000	-
Feb 14, 2024	orbimed advisors llc	sold	-	-	-17,713,600	-
Nov 06, 2023	shakespeare william	acquired	80,346	0.32	251,084	see remarks
Jul 17, 2023	gordon carl l	bought	1,463,790	3.05	479,932	-
Jul 17, 2023	orbimed advisors llc	bought	1,463,790	3.05	479,932	-
Jul 17, 2023	foresite capital management v, llc	bought	2,079,000	2.97	700,000	-
Dec 30, 2022	hayden donald j jr	bought	49,489	4.9989	9,900	-

Which funds bought or sold THRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	BML Capital Management, LLC	sold off	-100	-4,488,700	-	-%
Apr 23, 2024	AMALGAMATED BANK	sold off	-100	-7,000	-	-%
Apr 19, 2024	DENALI ADVISORS LLC	sold off	-100	-420,390	-	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	sold off	-100	-196,466	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	3,714	3,714	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.81	1,099,240	3,221,970	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	new	-	137,554	137,554	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	13,574	40,743	-%
Feb 26, 2024	Virtu Financial LLC	new	-	107,000	107,000	0.01%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	sold off	-100	-3,273,000	-	-%

Are Funds Buying or Selling THRX?

Are funds buying THRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own THRX

No. of Funds

Unveiling Theseus Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 16, 2024	tang capital partners lp	100%	100	SC 13D/A
Feb 13, 2024	frazier life sciences public fund, l.p.	0.0%	0	SC 13G/A
Jan 12, 2024	tang capital partners lp	7.3%	3,255,026	SC 13D/A
Dec 28, 2023	tang capital partners lp	7.3%	3,255,026	SC 13D/A
Dec 27, 2023	orbimed advisors llc	40.1%	17,713,600	SC 13D/A
Nov 24, 2023	orbimed advisors llc	40.1%	17,713,600	SC 13D/A
Nov 24, 2023	foresite capital fund v, l.p.	9.3%	4,108,796	SC 13D/A
Nov 24, 2023	tang capital partners lp	7.0%	3,101,606	SC 13D
Aug 10, 2023	fmr llc	-	0	SC 13G/A
Jul 19, 2023	foresite capital fund v, l.p.	9.4%	4,108,796	SC 13D/A

Recent SEC filings of Theseus Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
Feb 26, 2024	15-12G	15-12G
Feb 16, 2024	SC 13D/A	13D - Major Acquisition
Feb 15, 2024	EFFECT	EFFECT
Feb 14, 2024	25-NSE	25-NSE
Feb 14, 2024	4	Insider Trading
Feb 14, 2024	4	Insider Trading
Feb 14, 2024	4	Insider Trading
Feb 14, 2024	4	Insider Trading
Feb 14, 2024	4	Insider Trading
Feb 14, 2024	4	Insider Trading

Peers (Alternatives to Theseus Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.93	14.57	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.13	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Theseus Pharmaceuticals, Inc. News

Latest updates

Theseus Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet										(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-4.3%	235	245	256	222	230	238	248	251	98.00	-
Current Assets	-1.9%	210	214	242	202	-	-	-	-	-	-
Cash Equivalents	-1.2%	47.00	47.00	110	95.00	116	135	146	245	90.00	8.00
Net PPE	-5.3%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Liabilities	-8.0%	10.00	11.00	10.00	15.00	12.00	9.00	10.00	4.00	7.00	2.00
Current Liabilities	-8.8%	7.00	8.00	7.00	11.00	8.00	5.00	5.00	4.00	6.00	2.00
Shareholder's Equity	-4.1%	225	234	245	208	219	229	238	246	-	-
Retained Earnings	-9.6%	-155	-141	-126	-112	-98.50	-83.72	-72.10	-61.58	-52.92	-34.27
Additional Paid-In Capital	1.0%	380	376	372	320	318	313	310	308	3.00	-
Shares Outstanding	0.0%	44.00	44.00	44.00	39.00	39.00	38.00	38.00	39.00	-	2.00

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-9.5%	-11,026	-10,069	-18,600	-9,892	-7,226	-8,098	-7,684	-9,914	-5,321	-6,758	-5,200	-	-
Share Based Compensation	1.9%	3,640	3,573	2,993	2,375	1,800	2,518	2,044	1,584	1,535	500	500	-	-
Cashflow From Investing	119.4%	10,077	-51,939	-15,763	-11,134	-12,302	-3,161	-90,697	-	-	-	-	-	-
Cashflow From Financing	-100.0%	-	142	49,486	112	-	70.00	-	164,173	-1,483	1,195	99,892	-	-

THRX Income Statement

2023-09-30

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 11,519	$ 11,423	$ 36,839	$ 25,315
General and administrative	4,884	4,525	14,206	13,292
Total operating expenses	16,403	15,948	51,045	38,607
Loss from operations	(16,403)	(15,948)	(51,045)	(38,607)
Other income, net	2,899	1,203	8,150	1,716
Total other income, net	2,899	1,203	8,150	1,716
Net loss	(13,504)	(14,745)	(42,895)	(36,891)
Net loss attributable to common stockholders—basic	(13,504)	(14,745)	(42,895)	(36,891)
Net loss attributable to common stockholders—diluted	$ (13,504)	$ (14,745)	$ (42,895)	$ (36,891)
Weighted-average common stock outstanding—basic (in shares)	43,802,221	38,585,980	43,311,740	38,417,993
Weighted-average common stock outstanding—diluted (in shares)	43,802,221	38,585,980	43,311,740	38,417,993
Net loss per share attributable to common stockholders—basic (in usd per share)	$ (0.31)	$ (0.38)	$ (0.99)	$ (0.96)
Net loss per share attributable to common stockholders—diluted (in shares)	$ (0.31)	$ (0.38)	$ (0.99)	$ (0.96)
Comprehensive loss:
Net loss	$ (13,504)	$ (14,745)	$ (42,895)	$ (36,891)
Unrealized gain (loss) on marketable securities	216	(218)	41	(550)
Total comprehensive loss	$ (13,288)	$ (14,963)	$ (42,854)	$ (37,441)

THRX Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 46,893	$ 94,605
Short-term marketable securities	158,229	103,374
Prepaid expenses and other current assets	4,464	4,137
Total current assets	209,586	202,116
Property and equipment, net	414	416
Operating lease right-of-use asset	3,920	4,334
Long-term marketable securities	20,308	13,817
Other assets	399	1,764
Total assets	234,627	222,447
Current liabilities:
Accounts payable	1,313	4,973
Accrued expenses and other current liabilities	4,931	5,414
Operating lease liability, current portion	759	743
Total current liabilities	7,003	11,130
Operating lease liability, net of current portion	2,897	3,236
Restricted stock liability, net of current portion	205	466
Total liabilities	10,105	14,832
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 50,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 0 shares issued and outstanding as of September 30, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 43,605,080 and 38,734,446 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	4	4
Additional paid-in capital	379,944	320,183
Accumulated deficit	(155,081)	(112,186)
Accumulated other comprehensive loss	(345)	(386)
Total stockholders’ equity	224,522	207,615
Total liabilities and stockholders’ equity	$ 234,627	$ 222,447

About Theseus Pharmaceuticals, Inc.

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

CEO	Dr. Timothy P. Clackson Ph.D.
WEBSITE	https://theseusrx.com
INDUSTRY	Biotechnology
EMPLOYEES	38

Theseus Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Theseus Pharmaceuticals, Inc.? What does THRX stand for in stocks?

THRX is the stock ticker symbol of Theseus Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Theseus Pharmaceuticals, Inc. (THRX)?

As of Fri Feb 23 2024, market cap of Theseus Pharmaceuticals, Inc. is 179.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of THRX stock?

You can check THRX's fair value in chart for subscribers.

What is the fair value of THRX stock?

You can check THRX's fair value in chart for subscribers. The fair value of Theseus Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Theseus Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for THRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Theseus Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether THRX is over valued or under valued. Whether Theseus Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Theseus Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for THRX.